<DOC>
	<DOCNO>NCT02197572</DOCNO>
	<brief_summary>The purpose study characterize effect single dose 40 mg MLN0128 electrocardiographic QT/QTc interval participant advance solid tumor .</brief_summary>
	<brief_title>Effect MLN0128 QTc Interval Participants With Advanced Solid Tumors</brief_title>
	<detailed_description>The drug test study call MLN0128 . MLN0128 test determine effect single 40 mg dose electrocardiographic measure time start Q wave end T wave electrical cycle heart ( QT ) /rate correct QT ( QTc ) interval patient advance solid tumor . This study look electrocardiogram ( ECG ) result single dose MLN0128 . The study enroll approximately 30 patient . All participant receive single 40 mg dose MLN0128 capsule Day 1 . To avoid nausea vomiting , participant also administer 0.25 mg palonosetron Day 1 antiemetic agent . Participants may continue receive MLN0128 1 year dose 30 mg weekly clinical benefit derive . This multi-centre trial conduct United States . The overall time participate study 14 month . Participants make 6 visit clinic include end study visit 30 40 day last dose study drug follow-up assessment . Participants continue treatment MLN0128 continue make additional visit clinic twice every 4 week end study visit 30 40 day last dose study drug follow-up assessment .</detailed_description>
	<criteria>Inclusion Criteria 1 . Men woman participant 18 year old . 2 . Must radiographically clinically evaluable solid tumor Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 3 . Female participant : Are postmenopausal least 1 year screen visit , OR Are surgically sterile , OR If childbearing potential , agree practice 2 effective method contraception , time , time signing inform consent 3 month last dose study drug , OR Agree practice true abstinence , line prefer usual lifestyle participant . ( Periodic abstinence ( eg , calendar , ovulation , symptothermal , postovulation method ] withdrawal acceptable method contraception . ) 4 . Male participant , even surgically sterilize ( ie , status postvasectomy ) , : Agree practice effective barrier contraception entire study treatment period 3 month last dose study drug , Agree practice true abstinence , line prefer usual lifestyle participant . ( Periodic abstinence [ eg , calendar , ovulation , symptothermal , postovulation method female partner ] withdrawal acceptable method contraception . ) 5 . Voluntary write consent must give performance studyrelated procedure part standard medical care , understand consent may withdraw participant time without prejudice future medical care . 6 . Ability swallow oral medication , willingness perform mucositis prophylaxis , suitable venous access studyrequired blood sampling . Exclusion Criteria 1 . Female participant lactate breastfeed positive serum pregnancy test screening period . 2 . Any serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol . 3 . Treatment investigational product within 14 day first dose study drug systemic anticancer therapy within 28 day first dose study drug . 4 . Untreated brain metastasis history leptomeningeal disease spinal cord compression . 5 . Tumors involvement mediastinum . 6 . Failure recover reversible effect prior anticancer therapy exception alopecia , aftereffect associate prior tyrosine kinase inhibitor therapy hair depigmentation , hypothyroidism , and/or splinter hemorrhage . 7 . Systemic corticosteroid ( inhaler allow ) within 7 day first dose study drug . 8 . Manifestations malabsorption due prior gastrointestinal ( GI ) surgery , GI disease , unknown reason may alter absorption MLN0128 . 9 . Diagnosis diabetes mellitus ; participant history transient glucose intolerance due corticosteroid administration may enrol inclusion/exclusion criterion meet . 10 . Significant active cardiovascular pulmonary disease study entry â—¦ History arrhythmia require implantable cardiac defibrillator 11 . Clinically significant comorbidities uncontrolled pulmonary disease , active central nervous system disease , active infection , serious infection within 14 day first dose study drug , condition could compromise study participation participant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>